Zeneca launching Sular (nisoldipine) extended-release calcium channel blocker in January.
Executive Summary
ZENECA's SULAR (NISOLDIPINE) CCB WILL BE LAUNCHED IN JANUARY following a final agreement between Zeneca and Bayer AG giving Zeneca U.S. marketing and NDA rights to the once-daily calcium channel blocker. Zeneca is negotiating with Bayer for rights in other countries. Sular joins Zeneca's cardiovascular line of the ACE inhibitor Zestril (lisinopril), the ACE/diuretic combo Zestoretic, the beta-blocker Tenormin (atenolol), its diuretic combo Tenoretic and the nitrate Sorbitrate (isosorbide dinitrate).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth